<DOC>
	<DOCNO>NCT01541215</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial ass efficacy safety liraglutide paediatric population order potentially address unmet need treatment child adolescent type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Liraglutide Combination With Metformin Compared Metformin Alone , Children Adolescents With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Children adolescent age 1016 year . Subjects turn 17 year 11 month end treatment ( 52 week ) Diagnosis type 2 diabetes mellitus treat least 30 day : diet exercise alone , diet exercise combination metformin monotherapy , diet exercise combination metformin stable ( Stable define basal insulin adjustment 15 % ) dose basal insulin , diet exercise combination stable ( Stable define basal insulin adjustment 15 % ) dose basal insulin HbA1c : 7.011 % ( inclusive ) diet exercise treat 6.511 % ( inclusive ) treat metformin monotherapy , basal insulin monotherapy metformin basal insulin combination Body mass index ( BMI ) 85 % percentile general age gender match population Type 1 diabetes Maturity onset diabetes young ( MODY ) Use antidiabetic agent metformin and/or basal insulin within 90 day prior screen Recurrent severe hypoglycaemia hypoglycaemic unawareness judge investigator History chronic pancreatitis idiopathic acute pancreatitis Any clinically significant disorder , except condition associate type 2 diabetes history investigator 's opinion could interfere result trial Uncontrolled hypertension , treat untreated 99th percentile age gender child Known suspect abuse alcohol drugs/narcotics</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>